Study of real world efficacy and drug resistance associated substitutions of Sofosbuvir and Velpatasvir treatment for patients with HCV infection

Study of real world efficacy and drug resistance associated substitutions of Sofosbuvir and Velpatasvir treatment for patients with HCV infection - Study of real world efficacy and drug resistance associated substitutions of Sofosbuvir and Velpatasvir treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035511

Enrollment

200

Registered

2019-01-15

Start date

2019-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients were 20 years age <= HCV infected patients.

Exclusion criteria

Exclusion criteria: Patients with coinfection with hepatitis B virus or human immunodeficiency virus, autoimmune hepatitis, primary biliary cirrhosis, hemochromatosis or Wilson's disease were excluded. Patients with uncontrollable hypertension or diabetes mellitus and those with a history of alcohol abuse were also excluded.

Design outcomes

Primary

Measure	Time frame
Sustained virological response rates :after 12 weeks of end of treatment	—

Secondary

Measure	Time frame
Liver function change between before and after treatment. Liver cirrhosis associated events.Presence of resistance-associated substitutions	—

Countries

Japan

Contacts

Public ContactHIDEKI Fujii

Kyoto Prefectural University of Medicine Department of Molecular Gastroenterology and Hepatology

fuhideki@koto.kpu-m.ac.jp075-251-5519

Outcome results